| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-07-2391 |
| P698 | PubMed publication ID | 18723486 |
| P2093 | author name string | Patrick O'Connor | |
| Ping Chen | |||
| Eugenia Kraynov | |||
| Kenna Anderes | |||
| Enhong Chen | |||
| Alessandra Blasina | |||
| Tim Nichols | |||
| Jill Hallin | |||
| Sacha Ninkovic | |||
| James Register | |||
| Stephan Grant | |||
| Maria Elena Arango | |||
| P433 | issue | 8 | |
| P921 | main subject | DNA damage | Q5205747 |
| P304 | page(s) | 2394-2404 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. | |
| P478 | volume | 7 |
| Q89949443 | A Flexible Workflow for Automated Bioluminescent Kinase Selectivity Profiling |
| Q28817178 | A Surveillance Mechanism Ensures Repair of DNA Lesions during Zygotic Reprogramming |
| Q42659082 | A new in vitro system for activating the cell cycle checkpoint |
| Q35537834 | A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells |
| Q58119442 | ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells |
| Q61660000 | ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells |
| Q55505997 | ATR is required to complete meiotic recombination in mice. |
| Q39604095 | ATR mediates cisplatin resistance in a p53 genotype-specific manner |
| Q33691507 | ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine |
| Q47622968 | ATR/CHK1 inhibitors and cancer therapy |
| Q37860458 | Anticancer therapy with checkpoint inhibitors: what, where and when? |
| Q35023976 | Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition |
| Q33864110 | Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906. |
| Q38930942 | Bimodal regulation of p21(waf1) protein as function of DNA damage levels |
| Q37103465 | CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors |
| Q36328196 | CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. |
| Q39164107 | CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A. |
| Q28078268 | Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword |
| Q35972102 | Cell death signaling and anticancer therapy |
| Q30540593 | Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override |
| Q21245716 | Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy |
| Q36545701 | Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736 |
| Q42517538 | Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients |
| Q47100853 | Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. |
| Q37877694 | Checkpoint kinase inhibitors: a patent review (2009 – 2010) |
| Q37481298 | Checkpoint kinase inhibitors: a review of the patent literature |
| Q26863501 | Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising |
| Q58801115 | Chk-mate on resistance to kinase inhibitors |
| Q34062570 | Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers |
| Q30570001 | Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death |
| Q39858700 | Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival |
| Q92289996 | Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells |
| Q60447884 | Cobalt and Zinc Compounds Bearing 1,10-Phenanthroline-5,6-dione or 1,3,5-Triaza-7-phosphaadamantane Derivatives - Synthesis, Characterization, Cytotoxicity, and Cell Selectivity Studies |
| Q39131426 | Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line |
| Q35740025 | Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma |
| Q27665373 | Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor |
| Q38698806 | Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint. |
| Q28829581 | DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression |
| Q38073315 | DNA Double Strand Break Repair: A Radiation Perspective |
| Q96168423 | DNA damage checkpoint kinases in cancer |
| Q38061847 | DNA repair dysregulation from cancer driver to therapeutic target |
| Q38652528 | DNA replication stress and cancer: cause or cure? |
| Q88500255 | DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer |
| Q28298703 | Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics |
| Q40794273 | Defective Cell Cycle Checkpoints as Targets for Anti-Cancer Therapies |
| Q41761375 | Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. |
| Q39731432 | Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode. |
| Q27335118 | Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine |
| Q92689915 | E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
| Q34366587 | Effects of Chk1 inhibition on the temporal duration of radiation-induced G2 arrest in HeLa cells |
| Q39490308 | Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells |
| Q35832805 | Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer |
| Q27678684 | Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2 |
| Q34564108 | Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cells |
| Q34755147 | Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. |
| Q39112878 | HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1 |
| Q37785490 | Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes |
| Q35212640 | Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines |
| Q46146825 | Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors |
| Q36546469 | Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design |
| Q51338093 | In Silico Exploration of 1,7-Diazacarbazole Analogs as Checkpoint Kinase 1 Inhibitors by Using 3D QSAR, Molecular Docking Study, and Molecular Dynamics Simulations. |
| Q36255484 | In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia |
| Q54117559 | Inhibition of DNA‑PK activity sensitizes A549 cells to X‑ray irradiation by inducing the ATM‑dependent DNA damage response |
| Q39598327 | Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy |
| Q92369681 | Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin |
| Q38986400 | Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells |
| Q91753666 | Kinome expression profiling to target new therapeutic avenues in multiple myeloma |
| Q35149603 | Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. |
| Q34972637 | MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest |
| Q33926817 | Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. |
| Q52428057 | Modeling Therapy Resistance in BRCA1/2-Mutant Cancers |
| Q36792626 | Molecular Targets and Mechanisms of Radiosensitization Using DNA Damage Response Pathways |
| Q27014080 | Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response |
| Q41342397 | NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. |
| Q37201479 | Neuroblastoma and MYCN |
| Q34129155 | New insights into checkpoint kinase 1 in the DNA damage response signaling network |
| Q33794733 | New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells |
| Q92126687 | Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer |
| Q28066320 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer |
| Q38983310 | Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer |
| Q37622879 | Predicting response to radiotherapy: evolutions and revolutions |
| Q30498021 | RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins |
| Q30584974 | Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints |
| Q35353424 | Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition |
| Q35737519 | Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. |
| Q36088183 | Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition |
| Q89854426 | Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains |
| Q54536177 | Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis |
| Q27675773 | Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing |
| Q43216277 | Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors |
| Q26864870 | Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies |
| Q43973311 | Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine |
| Q40063670 | Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells |
| Q24657439 | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer |
| Q39044559 | Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss |
| Q38056316 | Targeting DNA repair mechanisms in cancer |
| Q38881119 | Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy |
| Q47120183 | Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer |
| Q38817102 | Targeting the ATR-CHK1 Axis in Cancer Therapy |
| Q26795781 | Targeting the Checkpoint to Kill Cancer Cells |
| Q39592286 | Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening |
| Q39338774 | The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells |
| Q37785502 | The DNA damage response—Repair or despair? |
| Q24310746 | The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress |
| Q28289090 | The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design |
| Q36771796 | The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma |
| Q38091705 | Therapeutic Agents Triggering Nonapoptotic Cancer Cell Death |
| Q38660811 | Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors |
| Q35232784 | Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells |
| Q26745686 | Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy |
| Q45971976 | UVB and caffeine: inhibiting the DNA damage response to protect against the adverse effects of UVB. |
| Q34045669 | p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells |
| Q35201518 | γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments |
Search more.